Unichem Laboratories (BOM:506690) ROCE % : 11.01% (As of Dec. 2024)

View and export this data going back to 1991. Start your Free Trial

What is Unichem Laboratories ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Unichem Laboratories's annualized ROCE % for the quarter that ended in Dec. 2024 was 11.01%.

Unichem Laboratories ROCE % Historical Data

The historical data trend for Unichem Laboratories's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Unichem Laboratories ROCE % Chart

Unichem Laboratories Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

ROCE %

Get a 7-Day Free Trial

-1.57

2.15

1.00

-6.02

-1.58

Unichem Laboratories Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROCE %	Get a 7-Day Free Trial															12.52	-17.21	3.09	6.07	11.01

Unichem Laboratories ROCE % Calculation

Unichem Laboratories's annualized ROCE % for the fiscal year that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2024 )		(A: Mar. 2023 )		(A: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2024 )		(A: Mar. 2023 )		(A: Mar. 2024 )
	=	-395.114	/	( ( (31930.489 - 6396.008)	+	(31693.441 - 7078.787) )	/ 2 )
	=	-395.114	/	( (25534.481	+	24614.654)	/ 2 )
	=	-395.114	/	25074.5675
	=	-1.58 %

Unichem Laboratories's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	2744	/	( ( (33109.6 - 8196)	+	(0 - 0) )	/ 1 )
	=	2744	/	( ( 24913.6	+	0 )	/ 1 )
	=	2744	/	24913.6
	=	11.01 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

Unichem Laboratories (BOM:506690) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Unichem Laboratories ROCE % Related Terms

Thank you for viewing the detailed overview of Unichem Laboratories's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Unichem Laboratories Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Unichem Laboratories Ltd (BOM:506690) » Definitions » ROCE %

Traded in Other Exchanges

UNICHEMLAB:India

Address

Off. S. V. Road, Unichem Bhavan, Prabhat Estate, Jogeshwari (West), Mumbai, MH, IND, 400 102

Website

https://www.unichemlabs.com

Unichem Laboratories Ltd is an India based pharmaceutical company. It manufactures a range of Active Pharmaceutical Ingredients (APIs). The company's products are offered in the areas of gastroenterology, cardiology, diabetology, psychiatry, neurology, anti-bacterial, anti-infectives and pain management. Some of its products include Apixaban, Brimonidine Tartrate, Finofibrate, Glipizide, Piroxicam and others. The company has a global market presence with sales in India and outside India, and the majority of the revenue derived from India. Its product categories comprises Formulations and Bulk Drugs and Chemicals.

Unichem Laboratories Headlines

No Headlines